About Us

Our Vision

The overarching aim of NIMIA is the introduction of novel digital biomarkers forming prognostic models that can identify the Multiple Sclerosis (MS) progression from the pre-clinical phase to early MS and later stages. 

The long-term goal of NIMIA is to develop, apply and validate a set of digital biomarkers that will allow comprehensive monitoring of disease activity, including the timely detection of relapses, the transitioning of RRMS to SPMS, and the continuous assessment of important health-related variables. Thus, NIMIA will transform the everyday management of MS, introducing a personalized and holistic approach in line with the principles of precision medicine. One particularly important aspect of NIMIA for both the preclinical and clinical arms of the study is the active engagement of patients in the process of disease monitoring and management with the creation of the NIMIA Community under a co-creation approach. Giving people living with MS the opportunity to actively engage in understanding and managing their disease can be empowering and is increasingly important, as therapeutic decisions are now mostly made in partnership between the doctor and the patient.

Dive into our World

Benefits of our products

Assists in understanding disease heterogeneity across diverse populations, including in the study people spanning the whole spectrum of disease severity and all forms of MS and monitoring them over time

Combines ecologically collected big data and relevant clinical data of existing repositories with advanced digital tools and explainable AI (xAI), under ethical and fair learning principles, providing prognostic models and actionable clinical insights towards precision medicine tailored to individuals’ needs and informed therapeutic strategies

Actively involves MS patients in all steps of the project realization, under a co-creation model that spans from the functional/non-functional user requirements, integrated architecture, increased user experience, to solution satisfaction and acceptance for the endorsement of patient-centric tools and interventions

Contributes to care coordination and the continuum of communication between MS patients and their physicians, with timely and longitudinal information, supporting lifestyle modifications to benefit wellness

Introduces sensitive, valid and clinically meaningful digital biomarkers for MS-related symptoms and prognostic models for early warning and tracking of symptoms deterioration

Correlates the digital biomarkers with the rehabilitation therapies and personalized interventions to assess their effectiveness in symptoms reversal and functional impact, ensuring patient compliance